MedPath

ShiJiaZhuang YiLing Pharmaceutical Co., Ltd

🇨🇳China
Ownership
-
Established
2001-08-28
Employees
10.8K
Market Cap
-
Website
www.yiling.cn
Introduction

The company was founded on June 16, 1992. The company took “inheriting innovation and benefiting humanity” as the corporate purpose, “science and technology for a healthy tomorrow”, “seeking development for employees, contributing to society, and creating value for shareholders” as the business philosophy, always adhering to the innovative development strategy of leading technology and market leaders. For the first time, the company systematically constructed a complex disease theory system, and founded a five-in-one “theory - clinical research - industry - teaching” industrial development cluster “from medicine to medicine to health”. “Traditional Chinese medicine complex disease diagnosis and treatment methods” are included in the national intangible cultural Heritage, Complexology 》It became a university textbook, and courses have been launched at more than 40 colleges and universities across the country. The company's main business is R&D, production and sales of patented innovative traditional Chinese medicines. The company's main products include Tongxinluo capsules, Shensong Yangxin capsules, Qiangxin capsules, Lianhua Qingfeng capsules, Lianhua Qingfeng capsules, Lianhua Cough tablets, Jinlida granules, Tongluo Mingmu capsules, Kidney Health Relief Tablets, Antidepressant capsules, Zizheng Anshen Oral Liquid OTC products, Yangzheng Anshen capsules, Shenling Blue capsules, Bazi Kidney Supplements capsules, Xia Li Qi capsules, etc. Corporate honors: Ranked first in the “2023 Chinese Medicine Innovative Brand Enterprise” list, won the “Top 100 Most Valuable Companies on the Main Board”, was selected for the “Top 100 Companies in China Pharmaceutical Industry Quality Award”, selected as “2023 Top 30 Pharmaceutical Industry Competitiveness”, ranked 5th in the 2022 Chinese Traditional Chinese Medicine Enterprise TOP100 list, selected for the CCTV “China ESG Listed Companies Pioneer 100” list, and was selected for the China Top 100 Innovative Brands, selected for the Xinhua News Agency Brand Project, Hebei Enterprise Technology Innovation Award, National Advanced Private Enterprise for Employment and Social Security, 2020 In July, Eling Pharmaceutical ranked 10th in the “2019 Top 100 Chinese Medicine Companies List” (China Pharmaceutical Industry Top 100 Series List) and won the honorary title of “High-Level Innovation Team”.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

90

NMPA:90

Drug Approvals

Ciprofloxacin Hydrochloride Tablets

Product Name
盐酸环丙沙星片
Approval Number
国药准字H20054497
Approval Date
Nov 12, 2024
NMPA

Metformin Hydrochloride Tablets

Product Name
盐酸二甲双胍片
Approval Number
国药准字H20054790
Approval Date
Nov 12, 2024
NMPA

消渴灵片

Approval Number
国药准字Z20054094
Approval Date
Oct 11, 2024
NMPA

加味银翘片

Approval Number
国药准字Z20044261
Approval Date
Oct 11, 2024
NMPA

三七片

Approval Number
国药准字Z20053987
Approval Date
Oct 11, 2024
NMPA

夏桑菊颗粒

Approval Number
国药准字Z20043491
Approval Date
Oct 11, 2024
NMPA

板蓝根颗粒

Approval Number
国药准字Z20043148
Approval Date
Oct 11, 2024
NMPA

银杏叶片

Approval Number
国药准字Z20063084
Approval Date
Sep 30, 2024
NMPA

通心络胶囊

Approval Number
国药准字Z19980015
Approval Date
Sep 30, 2024
NMPA

芪苈强心胶囊

Approval Number
国药准字Z20040141
Approval Date
Sep 30, 2024
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.